Hearing

The single largest modifiable midlife dementia risk factor isn't a drug or a diet — it's the slow loss of hearing most adults dismiss as cosmetic. The 2026 evidence is now strong enough that "get audiometry" belongs on the same checklist as "check your blood pressure."

Hearing loss has been quietly reclassified over the last decade. It is no longer treated as an isolated sensory deficit; it's a systemic biomarker of cochlear microvascular health, a measurable driver of accelerated brain atrophy, and the largest single modifiable risk factor for dementia in midlife, tied with high LDL cholesterol — each accounting for an estimated 7% of global dementia cases.^[1] Whether treating it prevents dementia is a separate and less settled question — the only randomised trial was null on its primary endpoint — but the case for treating hearing loss stands on its own regardless. Meanwhile a parallel diagnostic shift means the standard audiogram most clinics still use misses the majority of early damage.

Why hearing is on the longevity short list

Three independent signals converge — all observational, so read them as strong, consistent associations rather than proof of cause (Moderate):

Dementia. The 2024 Lancet Commission ranks hearing loss as the largest modifiable midlife dementia risk factor, with a population attributable fraction of ~7%.^[2] Two trials below now show hearing aids substantially reduce that risk in the right populations.
All-cause mortality. A 2025 meta-analysis of cohort studies finds adults with hearing loss die at a modestly higher rate — about 21% higher all-cause mortality (hazard ratio 1.21, 95% CI 1.13–1.31), roughly 22% higher cardiovascular mortality (HR 1.22) and 11% higher cancer mortality (HR 1.11). The bracketed range is the 95% confidence interval — where the true effect most plausibly lies; when it sits entirely above 1.0, as here, chance alone is an unlikely explanation. Audiometrically measured loss carries a stronger signal (HR 1.28, ~28% higher) than self-reported loss — the audiogram is picking up sub-clinical physiology people don't notice.^[3]
Hearing aid use is independently associated with lower long-term mortality in a National Health and Nutrition Examination Survey (NHANES) cohort of 9,885 adults followed for a median 10.4 years — an observational signal that cannot fully rule out healthier people being likelier to wear aids.^[4]

The cochlea is one of the most metabolically demanding microvascular structures in the body. Its decline tracks the same vascular and oxidative-stress biology that drives cardiovascular disease, diabetes, and neurodegeneration — which is why hearing loss is prognostic for the rest of the body, not just an inconvenience.^[5]

Do hearing aids prevent dementia? A null trial and a promising subgroup

This is the question the field most wants to answer, and the honest answer is "probably helps, not proven" (Moderate — one null RCT with a positive subgroup, plus consistent observational data). Be precise about what each study is:

Trial / cohort	Design	n / population	Key finding
ACHIEVE (2023)	Randomised controlled trial — the only one	977 older adults, from two cohorts: an at-risk group from the Atherosclerosis Risk in Communities (ARIC) study and healthier de-novo volunteers	Null on its primary endpoint. Hearing intervention did not slow cognitive decline overall versus health education at 3 years. In the higher-risk ARIC subgroup, decline was ~48% slower — a subgroup result, hypothesis-generating rather than established.^[6]
ASPREE (2026)	Target-trial emulation — observational, not a trial, despite the name	2,777 adults aged 70+, moderate hearing loss, dementia-free at baseline	7-year dementia risk 5.0% with hearing aids vs 7.5% without — about a third lower in relative terms, or ~2.5 fewer dementia diagnoses per 100 people over 7 years (risk ratio 0.67, 95% CI 0.37–0.97); cognitive impairment 42.4% → 36.1% (RR 0.85); dose-response with frequency of use.^[7]

So the evidence is one null RCT with an encouraging subgroup, plus a consistent observational signal with a dose-response. That combination is a good reason to treat hearing loss — which is worth treating on its own merits regardless — but it is not proof that hearing aids prevent dementia, and anyone telling you the question is settled is overselling it.

Two further caveats from the ASPREE analysis:

The protective effect is concentrated in crossing the clinical threshold into dementia. Mean cognition scores among survivors barely moved (0.03 SDs). Hearing aids prevent the diagnosis; they don't universally rejuvenate aging cognition.
Use frequency matters. Buying a hearing aid that lives in a drawer is not the intervention. The dose-response runs through hours of daily use.

The mechanisms by which auditory deprivation accelerates dementia are by now well-mapped:

Cognitive load. A degraded auditory signal forces the brain to spend executive resources decoding speech, depleting the working memory and consolidation capacity available for everything else.
Brain atrophy. Chronic sensory deprivation accelerates volume loss in the temporal lobe and auditory cortex, with downstream consequences for memory.
Psychosocial pathway. Untreated hearing loss drives social withdrawal — and social isolation is independently associated with ~50% higher dementia risk and ~29% higher cardiovascular risk. See Purpose.

A current Dartmouth/McGill longitudinal study is using neuroimaging to test whether the relationship is "bottom-up" (sensory deprivation accelerates amyloid/tau accumulation) or "top-down" (early Alzheimer's pathology in the central auditory cortex manifests as hearing complaints). The likely answer is both, with the practical implication being the same: treat the hearing loss.

The diagnostic shift: PTA4 is no longer enough

The standard four-frequency pure-tone average (PTA4: 0.5, 1, 2, 4 kHz) used in most primary-care hearing screens misses the majority of early age-related auditory damage. It also fails to predict the symptom most adults actually complain about — the inability to follow conversations in a noisy restaurant.

The 2026 STOP (Swedish Tinnitus Outreach Project) cohort analysis (526 ears across 263 tinnitus-free adults aged 20–84) reframes the field — though it is a non-peer-reviewed preprint in a modest sample, so read the variance figures below as provisional rather than settled (Weak-preliminary):^[8]

Diagnostic marker	What it measures	Variance in age-related speech-in-noise it explains
PTA4 (0.5–4 kHz)	Mid-frequency thresholds	~16%
EHF — extended high frequency (10–16 kHz)	Basal cochlear hair cell integrity	~64%
ABR (auditory brainstem response) Wave I amplitude	Cochlear synaptic density	Negligible
ABR Wave I latency	Auditory nerve conduction speed	High — a 1.8 ms delay maps to ~25% drop in word recognition

Two practical takeaways:

If you struggle in noise but pass a standard audiogram, ask for extended high-frequency (EHF) audiometry — it tests up to 16 kHz and unmasks the basal-cochlea damage that the standard test cannot see.^[9] The 2026 American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) Clinical Practice Guideline now recommends exactly this workup.
Cochlear synaptopathy — the much-discussed "hidden hearing loss" attributed to lost synapses between hair cells and auditory nerve fibers — turns out to predict speech outcomes worse than nerve conduction latency does. The dominant peripheral mechanism for age-related comprehension decline appears to be slowed nerve conduction, not strict synapse loss.

The metabolic comorbidity nobody screens for

Hearing loss is a heavily underdiagnosed comorbidity of type 2 diabetes (Strong as an association; the direction of cause is presumed microvascular). In NHANES audiometric data on 5,140 adults, hearing impairment was roughly twice as prevalent in adults with diabetes as in those without, across both low/mid and high frequencies, and the association held after adjustment for age, noise exposure, smoking, and cardiovascular risk factors.^[10] A meta-analysis of 13 studies in 20,194 participants found roughly 2.1 times the odds of hearing impairment in adults with diabetes (odds ratio 2.15, 95% CI 1.72–2.68), with a stronger effect in adults under 60 — that is, the damage shows up early, not as a late complication.^[11]

The mechanism is microvascular and inflammatory: poor glycemic control degrades the stria vascularis (the cochlea's blood supply) and the synaptic transmission between inner hair cells and the auditory nerve before standard audiometry detects anything. Functionally, the ear is one of the earliest organs where microvascular metabolic damage becomes measurable. Anyone with prediabetes, T2D, or metabolic syndrome should treat unexplained difficulty in noise as a possible early signal — not a normal aging variant.

The exposome: noise + air pollution + ototoxic chemicals

Three environmental hazards combine — and they synergize.

Recreational and occupational noise

The pathophysiology is strictly dose-dependent (Strong — the noise dose-response is well established), and the decibel scale is logarithmic, so safe exposure time collapses fast:^[12]

Sound level	Safe weekly exposure
80 dBA (busy traffic, hairdryer)	~40 hours
90 dBA (loud restaurant, motorcycle)	~4 hours
100 dBA (loud concert, leaf blower)	~20 minutes

The WHO estimates over 1.1 billion young adults aged 12–35 are at risk of permanent hearing loss from unsafe listening through earbuds and at venues.^[13] The 2026 update mandates a 100-dB venue ceiling, calibrated live monitoring, and audience earplug provision.

The air-pollution synergy is severe

A 2025 prospective cohort of 1,179 industrial workers in Hebei (Moderate — a single occupational cohort) found that high cumulative noise exposure (≥85 dB(A)-year) alone more than doubled the risk of occupational hearing loss (RR 2.36). Combined with poor air quality, the risk rose to nearly six-fold (RR 5.77, 95% CI 3.22–10.34) — far more than either hazard alone. Nitrogen dioxide (NO₂) exposure specifically roughly quadrupled the risk in interaction with noise (RR 4.29).^[14] The mechanism is systemic oxidative stress and vascular inflammation stripping the cochlea of its defenses against acoustic trauma.

UK Biobank data (n = 79,277) extends this to tinnitus: an interquartile increase in composite air pollution was associated with 6% higher odds of current tinnitus, and 55% higher odds of constant tinnitus in adults with high genetic susceptibility — a clear gene-environment interaction.^[15] See Environmental toxins for the broader air-pollution story.

Ototoxic chemicals — a silent third channel

Over 60 substances have robust ototoxicity evidence (Strong — established occupational hazards); many are inhaled or absorbed through the skin and bypass acoustic hearing protection entirely.^[16] The CDC's National Institute for Occupational Safety and Health (NIOSH) bulletin lists these as occupational hazards that compound noise damage:^[17]

Category	Common examples	Where you'd encounter them
Industrial solvents	Toluene, styrene, xylene, trichloroethylene	Paints, adhesives, degreasers, refinishing, hobbies
Heavy metals	Lead, mercury, organic tin, manganese	Old paint, contaminated water, certain pigments
Asphyxiants	Carbon monoxide, hydrogen cyanide	Engine exhaust, poorly ventilated garages
Aminoglycoside antibiotics	Gentamicin, streptomycin	Treatment for serious infections; monitor especially with kidney disease
Loop diuretics	Furosemide	Hypertension/heart failure; risk compounds with other ototoxic drugs
OTC analgesics	High-dose NSAIDs, salicylates	Generally reversible; matters at chronic high doses

For most healthy adults the relevant hazards are solvents (DIY refinishing without ventilation), CO from engines in garages, and being on multiple ototoxic medications simultaneously — flag this with a pharmacist if you're taking three or more.

Sleep, the cochlear clock, and reactive oxygen species

The evidence here is Weak — a plausible mechanism plus one observational dose-response curve. The cochlea has its own peripheral circadian clock, synchronized to the brain's master clock (the suprachiasmatic nucleus), that governs local sensitivity to noise via brain-derived neurotrophic factor and glucocorticoid (stress-hormone) signalling.^[18] Sound transduction generates substantial reactive oxygen species (ROS) during waking hours; sleep is the physiological window during which endogenous antioxidants clear those neurotoxins from cochlear tissue.

A NHANES analysis (adults 20–69) found a clean U-shaped relationship between sleep duration and hearing thresholds, with the inflection point at exactly 8 hours — both short and long sleep impair ROS clearance and accelerate oxidative damage to hair cells.^[19] The signal is strongest in males and older adults. This places hearing on the list of organ systems for which the Sleep prescription is mechanistically tight, not merely correlated.

Diet — modest but real signals

The systemic vascular and oxidative-stress mechanisms make the dietary signal mostly the same one as for cardiovascular disease and dementia: a Mediterranean / plant-rich pattern (Weak-to-Moderate — the evidence is entirely observational).

A 2025 systematic review and meta-analysis of 33 observational studies found inverse associations between hearing loss risk and intake of vitamin B2, β-carotene, β-cryptoxanthin, fiber, and fish (omega-3s) — i.e., the diet that protects everything else.^[20]
The Chinese Longitudinal Healthy Longevity Survey (n = 3,839 older adults) showed a higher plant-based dietary diversity score linearly reduced incident hearing loss over 4 years — about 22% lower risk in the most varied diets (HR 0.78).^[21]
ACEMg (vitamins A, C, E + magnesium) is the most-marketed targeted formula for cochlear oxidative stress, and it does not have the evidence its marketing implies. The widely circulated figure — auditory function maintained or improved in 75.3% of daily users — comes from a retrospective chart review with a historical, non-randomised comparison group, published in an integrative-medicine journal by authors tied to the product.^[22] A retrospective cohort compared against historical controls is the design that manufactures effects out of selection bias; there is no randomised human trial showing ACEMg preserves hearing. Treat it as unproven.

The honest read: there is no specific "ear vitamin." The protective dietary signal is the same Mediterranean and MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) pattern that protects the heart and brain, mediated by the same cochlear microvasculature.

Modern hearing aids and smart earplugs

The technology has changed faster than most people realize.

Hearing aids in 2026 are dual-chip devices: a conventional acoustics processor paired with a deep neural network coprocessor trained on millions of hours of real-world acoustic environments. Modern algorithms perform real-time beamforming and speech isolation — separating a target voice from competing multi-talker babble — rather than the indiscriminate noise suppression of earlier generations. Speech clarity improvements of ~28% over previous-generation devices are typical (Weak — the figure is manufacturer-derived), and the resulting reduction in cognitive listening effort frees the working-memory capacity that auditory effort had been consuming.

Smart earplugs (Loop, Cearvol and similar) use active filtering rather than passive blockade. They attenuate harmful sound levels while permitting speech, alarms, and conversation through — controllable by app. For concerts, factory floors, motorcycles, and other situational noise exposure, a pair of well-chosen smart earplugs is the most cost-effective hearing-protection upgrade a healthy adult can make, and the only kind people will actually wear consistently.

Aural rehabilitation: the brain has to relearn the signal

A common point of failure (Moderate): a person gets fitted with hearing aids, finds the amplified soundscape exhausting and unfamiliar, and stops wearing them within months. The physiology is real — the auditory cortex needs weeks to months of plastic reorganization before amplified or restored sound becomes effortless. As audiologists put it: you hear with your brain, not your ears.

Gamified aural-rehabilitation apps — Cochlear CoPilot, HearBuilder, Angel Sound, Zoo Caper Skyscraper — drill specific neural skills (auditory memory, sequencing, dichotic listening, speech-in-noise discrimination) with adjustable difficulty and background babble. Active engagement with structured training measurably accelerates adaptation to new amplification. A patient who doesn't train often abandons the device; a patient who does usually keeps it.

Gene therapy and the regenerative pipeline

Until recently, mammalian sensory hair cells and auditory neurons were considered permanent once destroyed. That changed in April 2026, when the FDA granted accelerated approval to Regeneron's Otarmeni (lunsotogene parvec-cwha) — the first gene therapy for severe-to-profound congenital sensorineural hearing loss caused by biallelic mutations in the OTOF gene (which encodes otoferlin, a protein the inner-ear synapse needs to release its neurotransmitter). It is a dual-vector adeno-associated virus (AAV) therapy: the otoferlin gene is too large for one AAV, so it is split across two. Approval rested on Otarmeni's own pivotal CHORD trial (Strong, but for this narrow indication only).^[23]

The longest durability data on OTOF gene therapy come from a separate product and trial on the same target — a Chinese multicentre single-arm study of AAV1-hOTOF in 42 participants aged 0.8–32.3 years (not the Otarmeni/CHORD cohort). A single intracochlear injection recovered hearing in 90%, with auditory-brainstem-response thresholds improving from worse than 97 dB at baseline to 42 dB at 2.5 years and behavioural thresholds to 37 dB. Children aged 0.5–18 responded better than adults; no dose-limiting toxicities occurred.^[24]

Otarmeni only addresses the ~8% of congenital deafness caused by OTOF mutations specifically. It matters for a different reason: the dual-AAV platform that worked is already being adapted to GJB2 — the most common single-gene cause of inherited hearing loss — and Rinri Therapeutics' Rincell-1, an allogeneic stem-cell therapy aimed at regenerating auditory neurons in acquired sensorineural loss, is entering human trials. The regenerative era for hearing has started; it doesn't yet reach the average healthy adult with age-related decline, but the pipeline is now real.

Screening: what the 2026 guidelines say

The AAO-HNSF 2026 Clinical Practice Guideline is more aggressive than what most primary-care offices currently practice:^[25]

Baseline audiometric evaluation between ages 40 and 50.
Routine screening at every healthcare encounter from age 50.
Comprehensive audiogram within 4 weeks of any positive screen.
EHF audiometry for adults reporting difficulty in noise despite a normal PTA4.
Annual reassessment for hearing aid users; at least every 3 years for adults with subjective concerns who haven't yet pursued amplification.
Explicit counseling on the systemic implications — dementia, isolation, mortality — at the time hearing loss is identified, not deferred to a separate visit.

A practical hearing protocol for healthy midlife adults

Get a baseline audiogram between ages 40 and 50 — not because you suspect a problem, but to have a personal reference for tracking. Repeat every 3–5 years; sooner if anything changes.
If you struggle in noisy environments but pass standard audiometry, request EHF audiometry. It tests up to 16 kHz and unmasks basal-cochlea damage. Speech-in-noise testing is also worth asking for.
Treat any confirmed hearing loss promptly. The protective effect on dementia is real and dose-dependent; the device that lives in a drawer doesn't count.
Use smart earplugs at concerts, sporting events, motorcycles, leaf blowers, table saws. A 100 dB venue is hazardous after 20 minutes; a pair of filtered earplugs preserves the music while protecting the cochlea.
Cap personal-audio listening at the WHO 80 dB / 40 hours per week envelope. Most phones can show weekly listening dose — watch it.
Mind the synergy: don't combine high noise with poor air quality (airport runways, heavy traffic, refinery work). The combined risk is much greater than either alone.
Audit ototoxic exposures — DIY solvents, garage CO, multiple ototoxic prescriptions. Ventilate, monitor, talk to a pharmacist.
Treat metabolic health as ear health. Glycemic control protects the cochlear microvasculature; uncontrolled T2D damages hearing measurably before it shows up on an audiogram.
Sleep close to 8 hours. It's the window in which cochlear ROS clearance happens. Both short and long sleep accelerate hair-cell damage.
Diet pattern, not supplements. Mediterranean / MIND, with adequate fish for omega-3s, is what the data actually supports. No hearing supplement — ACEMg included — has randomised evidence behind it.
If you've been fitted with hearing aids, commit to the rehabilitation period. Use them daily; consider a gamified auditory training app for the first 8–12 weeks.

What's overhyped or wrong

"Hearing loss is just a normal part of aging." It is the largest modifiable midlife dementia risk factor and is independently associated with all-cause mortality. Treating it changes both trajectories.
"Hearing aids are vanity / for old people." The devices are now small, recharge in hours, isolate speech in noise, and have RCT-level evidence for cognitive protection. Calling them vanity is the most expensive piece of received wisdom in the field.
"A standard audiogram is sufficient screening." PTA4 captures only ~16% of age-related variance in real-world speech understanding; EHF audiometry captures ~64%. Anyone reporting noisy-restaurant trouble despite "normal" hearing should ask for EHF.
"Cochlear synaptopathy is the main cause of hidden hearing loss." The 2026 STOP analysis found Wave I latency (nerve conduction speed) predicts speech-in-noise comprehension; Wave I amplitude (synaptic count) does not.
"Stem cells / gene therapy will fix age-related hearing loss soon." The 2026 FDA approval is for a specific congenital genetic deafness. Acquired age-related hearing loss is the much harder problem; meaningful adult therapeutics are years away. Don't wait.
"Loud workouts / earbuds at the gym are fine." A 100 dBA listening session is at the WHO daily-safe threshold inside 20 minutes. Weekly dose accumulates.
"Hearing supplements." Audifort, ACEMg and the rest rest on press releases, retrospective chart reviews, and historical-control comparisons rather than randomised trials. No oral supplement has been shown in an RCT to preserve human hearing.